PDCD1 and hepatocellular carcinoma: To the best of our knowledge, this is the first preclinical study to evaluate the therapeutic efficacy of triple immunotherapy with anti-PD-1 mAb, a STING agonist, and anti-LAG-3 mAb in a murine HCC model using LAG-3-targeting PET imaging.